SciFluor banks $5M for new drug technology

The upstart SciFluor Life Sciences has garnered a $5 million Series A round from Allied Minds. The money will be used to advance new fluorination technology developed at Harvard University in the lab of Tobias Ritter. According to its release, adding fluorine to molecules can make a key difference on a score of points: improved metabolic stability, potency, binding affinity, bioavailability and blood-brain barrier penetration. "Late- or end-stage fluorination is a promising strategy to quickly access new drug candidates with potentially improved pharmacological profiles," said Dr. Ritter, scientific founder and chief technical officer of SciFluor. Dr. Ritter is an Associate Professor of Chemistry and Chemical Biology at Harvard. Release

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.